I. Beaulieu-boire and A. E. Lang, Behavioral effects of levodopa, Mov. Disord. Off. J. Mov. Disord. Soc, vol.30, pp.90-102, 2015.

E. Bezard, J. M. Brotchie, and C. E. Gross, Pathophysiology of levodopa-induced dyskinesia: potential for new therapies, Nat. Rev. Neurosci, vol.2, pp.577-588, 2001.

F. Blandini, M. Armentero, and E. Martignoni, The 6-hydroxydopamine model: News from the past, Parkinsonism Relat. Disord, vol.14, pp.124-129, 2008.

A. Bonito-oliva, D. Masini, and G. Fisone, A mouse model of non-motor symptoms in Parkinson's disease: focus on pharmacological interventions targeting affective dysfunctions, Front. Behav. Neurosci, vol.8, 2014.

R. Bordet, S. Ridray, S. Carboni, J. Diaz, P. Sokoloff et al., Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitization to levodopa, Proc. Natl. Acad. Sci. U. S. A, vol.94, pp.3363-3367, 1997.

R. Bordet, S. Ridray, J. C. Schwartz, and P. Sokoloff, Involvement of the direct striatonigral pathway in levodopa-induced sensitization in 6-hydroxydopamine-lesioned rats, Eur. J. Neurosci, vol.12, pp.2117-2123, 2000.

I. Branchi, I. D'andrea, M. Armida, T. Cassano, A. Pèzzola et al., Nonmotor symptoms in Parkinson's disease: investigating early-phase onset of behavioral dysfunction in the 6-hydroxydopamine-lesioned rat model, J. Neurosci. Res, vol.86, pp.2050-2061, 2008.

A. M. Brown, A. Y. Deutch, and R. J. Colbran, Dopamine depletion alters phosphorylation of striatal proteins in a model of Parkinsonism, Eur. J. Neurosci, vol.22, pp.247-256, 2005.

E. Bychkov, M. R. Ahmed, K. N. Dalby, and E. V. Gurevich, Dopamine depletion and subsequent treatment with L-DOPA, but not the long-lived dopamine agonist pergolide, enhances activity of the Akt pathway in the rat striatum, J. Neurochem, vol.102, pp.699-711, 2007.

S. Carnicella, G. Drui, S. Boulet, C. Carcenac, M. Favier et al., Implication of dopamine D3 receptor activation in the reversion of Parkinson's disease-related motivational deficits, Transl. Psychiatry, vol.4, pp.401-401, 2014.

M. M. Carvalho, F. L. Campos, B. Coimbra, J. M. Pêgo, C. Rodrigues et al., Behavioral characterization of the 6-hydroxidopamine model of Parkinson's disease and pharmacological rescuing of non-motor deficits, Mol. Neurodegener, vol.8, 2013.

C. Da-cunha, M. E. Angelucci, N. S. Canteras, S. Wonnacott, and R. N. Takahashi, The lesion of the rat substantia nigra pars compacta dopaminergic neurons as a model for Parkinson's disease memory disabilities, Cell. Mol. Neurobiol, vol.22, pp.227-237, 2002.

D. Dardou, L. Reyrolle, C. Chassain, and F. Durif, Chronic pramipexole treatment induces compulsive behavior in rats with 6-OHDA lesions of the substantia nigra and ventral tegmental area, Behav. Brain Res, vol.332, pp.327-336, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01690913

C. Delaville, J. Chetrit, K. Abdallah, S. Morin, L. Cardoit et al., Emerging dysfunctions consequent to combined monoaminergic depletions in Parkinsonism, Neurobiol. Dis, vol.45, pp.763-773, 2012.
URL : https://hal.archives-ouvertes.fr/hal-01178540

G. Drui, S. Carnicella, C. Carcenac, M. Favier, A. Bertrand et al., Loss of dopaminergic nigrostriatal neurons accounts for the motivational and affective deficits in Parkinson's disease, Mol. Psychiatry, 2013.

K. L. Eskow-jaunarajs, M. Angoa-perez, D. M. Kuhn, and C. Bishop, Potential mechanisms underlying anxiety and depression in Parkinson's disease: consequences of l-DOPA treatment, Neurosci. Biobehav. Rev, vol.35, pp.556-564, 2011.

K. L. Eskow-jaunarajs, K. B. Dupre, C. Y. Ostock, T. Button, T. Deak et al., Behavioral and neurochemical effects of chronic L-DOPA treatment on nonmotor sequelae in the hemiparkinsonian rat, Behav. Pharmacol, vol.21, pp.627-637, 2010.

K. L. Eskow-jaunarajs, J. A. George, and C. Bishop, L-DOPA-induced dysregulation of extrastriatal dopamine and serotonin and affective symptoms in a bilateral rat model of Parkinson's disease, Neuroscience, vol.218, pp.243-256, 2012.

A. H. Evans and A. J. Lees, Dopamine dysregulation syndrome in Parkinson's disease, Curr. Opin. Neurol, vol.17, pp.393-398, 2004.

E. Faggiani, C. Delaville, and A. Benazzouz, The combined depletion of monoamines alters the effectiveness of subthalamic deep brain stimulation, Neurobiol. Dis, vol.82, pp.342-348, 2015.

S. E. File, H. Zangrossi, M. Viana, and F. G. Graeff, Trial 2 in the elevated plus-maze: a different form of fear?, Psychopharmacology (Berl.), vol.111, pp.491-494, 1993.

D. C. German and K. F. Manaye, Midbrain dopaminergic neurons (nuclei A8, A9, and A10): threedimensional reconstruction in the rat, J Comp Neurol, vol.331, pp.297-309, 1993.

J. G. Goldman, C. L. Vaughan, and C. G. Goetz, An update expert opinion on management and research strategies in Parkinson's disease psychosis, Expert Opin. Pharmacother, vol.12, 2011.

V. S. Hernández, S. Luquín, F. Jáuregui-huerta, A. A. Corona-morales, M. P. Medina et al., Dopamine receptor dysregulation in hippocampus of aged rats underlies chronic pulsatile L-Dopa treatment induced cognitive and emotional alterations, Neuropharmacology, vol.82, pp.88-100, 2014.

S. K. Janhunen, H. Svärd, J. Talpos, G. Kumar, T. Steckler et al., The subchronic phencyclidine rat model: relevance for the assessment of novel therapeutics for cognitive impairment associated with schizophrenia, Psychopharmacology (Berl.), vol.232, pp.4059-4083, 2015.

T. A. Jenkins, M. K. Harte, C. E. Mckibben, J. J. Elliott, and G. P. Reynolds, Disturbances in social interaction occur along with pathophysiological deficits following sub-chronic phencyclidine administration in the rat, Behav. Brain Res, vol.194, pp.230-235, 2008.

S. Kuzuhara, Drug-induced psychotic symptoms in Parkinson's disease. Problems, management and dilemma, J. Neurol, vol.248, pp.28-31, 2001.

S. Loiodice, A. Denibaud, W. Deffains, M. Alix, P. Montagne et al., Validation of a New Scoring Scale for Behavioral Assessment of L-Dopa-Induced Dyskinesia in the Rat: A New Tool for Early Decision-Making in Drug Development, ACS Chem. Neurosci, vol.9, pp.762-772, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01693938

S. Loiodice, P. Mcghan, V. Gryshkova, R. Fleurance, D. Dardou et al., Striatal changes underlie MPEP-mediated suppression of the acquisition and expression of pramipexole-induced place preference in an alpha-synuclein rat model of Parkinson's disease, J. Psychopharmacol. Oxf. Engl, vol.31, pp.1323-1333, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01692847

S. Loiodice, P. Winlow, S. Dremier, E. Hanon, D. Dardou et al., Pramipexole induced place preference after L-dopa therapy and nigral dopaminergic loss: linking behavior to transcriptional modifications, Psychopharmacology (Berl.), pp.15-27, 2017.
DOI : 10.1007/s00213-016-4430-7
URL : https://hal.archives-ouvertes.fr/hal-01688687

R. Magnard, Y. Vachez, C. Carcenac, P. Krack, O. David et al., What can rodent models tell us about apathy and associated neuropsychiatric symptoms in Parkinson's disease?, Transl. Psychiatry, vol.6, 2016.

R. Martínez-fernández, E. Schmitt, P. Martinez-martin, and P. Krack, The hidden sister of motor fluctuations in Parkinson's disease: A review on nonmotor fluctuations, Mov. Disord. Off. J. Mov. Disord. Soc, vol.31, pp.1080-1094, 2016.

K. Mcfarland, D. L. Price, and D. W. Bonhaus, Pimavanserin, a 5-HT2A inverse agonist, reverses psychosis-like behaviors in a rodent model of Parkinson's disease, Behav. Pharmacol, vol.22, pp.681-692, 2011.

W. G. Meissner, M. Frasier, T. Gasser, C. G. Goetz, A. Lozano et al., Priorities in Parkinson's disease research, Nat. Rev. Drug Discov, vol.10, pp.377-393, 2011.

A. Michel, P. Downey, X. Van-damme, C. De-wolf, R. Schwarting et al., Behavioural Assessment of the A2a/NR2B Combination in the Unilateral 6-OHDA-Lesioned Rat Model: A New Method to Examine the Therapeutic Potential of Non-Dopaminergic Drugs, PLOS ONE, vol.10, 2015.

M. Nakashima, H. Imada, E. Shiraishi, Y. Ito, N. Suzuki et al., Phosphodiesterase 2A Inhibitor TAK-915 Ameliorates Cognitive Impairments and Social Withdrawal in N-Methyl-d-Aspartate Receptor Antagonist-Induced Rat Models of Schizophrenia, J. Pharmacol. Exp. Ther, vol.365, pp.179-188, 2018.

A. Nezhadi, V. Sheibani, K. Esmaeilpour, M. Shabani, and S. Esmaeili-mahani, Neurosteroid allopregnanolone attenuates cognitive dysfunctions in 6-OHDA-induced rat model of Parkinson's disease, Behav. Brain Res, vol.305, pp.258-264, 2016.

V. Paillé, V. Henry, L. Lescaudron, P. Brachet, and P. Damier, Rat model of Parkinson's disease with bilateral motor abnormalities, reversible with levodopa, and dyskinesias, Mov. Disord, vol.22, pp.533-539, 2007.

G. Paxinos and C. Watson, The Rat Brain in Stereotaxic Coordinates, 1998.

E. Y. Pioli, W. Meissner, R. Sohr, C. E. Gross, E. Bezard et al., Differential behavioral effects of partial bilateral lesions of ventral tegmental area or substantia nigra pars compacta in rats, Neuroscience, vol.153, pp.1213-1224, 2008.

R. B. Postuma and D. Berg, Advances in markers of prodromal Parkinson disease, Nat. Rev. Neurol, vol.12, pp.622-634, 2016.

O. Rascol, P. Payoux, F. Ory, J. J. Ferreira, C. Brefel-courbon et al., Limitations of current Parkinson's disease therapy, Ann. Neurol, vol.53, 2003.

V. Sgambato-faure, V. Buggia, F. Gilbert, D. Lévesque, A. Benabid et al., Coordinated and spatial upregulation of arc in striatonigral neurons correlates with L-dopa-induced behavioral sensitization in dyskinetic rats, J. Neuropathol. Exp. Neurol, vol.64, pp.936-947, 2005.
URL : https://hal.archives-ouvertes.fr/inserm-00391107

M. T. Tadaiesky, P. A. Dombrowski, C. P. Figueiredo, E. Cargnin-ferreira, C. Da-cunha et al., Emotional, cognitive and neurochemical alterations in a premotor stage model of Parkinson's disease, Neuroscience, vol.156, pp.830-840, 2008.

N. Titova, A. H. Schapira, K. R. Chaudhuri, M. A. Qamar, E. Katunina et al., Nonmotor Symptoms in Experimental Models of Parkinson's Disease, Int. Rev. Neurobiol, vol.133, pp.63-89, 2017.

J. M. Van-kampen and A. J. Stoessl, Effects of oligonucleotide antisense to dopamine D3 receptor mRNA in a rodent model of behavioural sensitization to levodopa, Neuroscience, vol.116, pp.307-314, 2003.

N. P. Visanji, J. Gomez-ramirez, T. H. Johnston, D. Pires, V. Voon et al., Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson's disease, Mov. Disord. Off. J. Mov. Disord. Soc, vol.21, pp.1879-1891, 2006.

C. Winter, A. Von-rumohr, A. Mundt, D. Petrus, J. Klein et al., Lesions of dopaminergic neurons in the substantia nigra pars compacta and in the ventral tegmental area enhance depressive-like behavior in rats, Behav. Brain Res, vol.184, pp.133-141, 2007.